查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1586002

COVID-19 疫苗市场：按产品类型、最终用户、患者类型 - 2025-2030 年全球预测

COVID-19 Vaccines Market by Product Type (Monovalent Vaccine, Multivalent Vaccine), End-User (Academic & Research Centers, Clinics, Hospitals), Patient Type - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年COVID-19疫苗市场规模为2,154.3亿美元，预计2024年将达到2,371.2亿美元，复合年增长率为10.55%，预计2030年将达4,348.3亿美元。

COVID-19 疫苗市场研究范围涵盖与疫苗开发、分销和采用相关的趋势、市场动态和消费行为分析。这些疫苗的需求对于全球公共卫生至关重要，旨在减轻病毒的传播并降低死亡率。 COVID-19 疫苗的最终用途涵盖一般人群、医疗保健部门、政府和私营部门，包括跨人口群体的广泛免疫、变异反应和潜在的加强剂量。市场洞察揭示了关键的成长要素，例如政府对疫苗创新的持续支持、公众意识的提高以及 mRNA 技术的进步。但透过与国际卫生组织的合作和改善供应链物流，也有新的机会来扩大疫苗接种到服务不足地区的机会。可以透过利用技术进步和策略联盟来加强分销网络来利用这些机会。限制包括因错误讯息、监管障碍以及储存和分发方面的后勤挑战而导致的疫苗接种犹豫，尤其是在偏远地区。此外，病毒的进化和新物种的出现正在改变疫苗的有效性，并带来需要持续研究和适应的挑战。为了克服这些挑战，公司可以在疫苗储存技术、供应链管理区块链以及人工智慧主导的适应性疫苗配方研究等领域进行创新。该市场的特点是快速发展和激烈竞争，参与者不断寻求增强其服务产品并扩大其区域影响力。製药公司和高科技公司之间的合作可以促进疫苗开发和分配效率的显着提高，从而提供一种全面的方法来对抗 COVID-19 及其不断变化的威胁。

主要市场统计
基准年[2023] 2154.3亿美元
预测年份 [2024] 2371.2亿美元
预测年份 [2030] 4,348.3亿美元
复合年增长率（%） 10.55%

市场动态：揭示快速发展的 COVID-19 疫苗市场的关键市场洞察

COVID-19 疫苗市场正在因供需的动态相互作用而发生转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 冠状病毒迅速传播导致大量死亡
    • 政府对 COVID-19 疫苗的支持和津贴
    • 加大疫苗研发倡议
  • 市场限制因素
    • 世界发展中地区的基础设施、技能和技术支援有限
  • 市场机会
    • 生产和销售 COVID-19 疫苗的合併活动增加
    • 加大疫苗投资
  • 市场挑战
    • 与 COVID-19 疫苗相关的副作用

波特五力：驾驭 COVID-19 疫苗市场的策略工具

波特五力框架是了解 COVID-19 疫苗市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解 COVID-19 疫苗市场的外部影响

外部宏观环境因素在塑造 COVID-19 疫苗市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解 COVID-19 疫苗市场的竞争格局

对 COVID-19 疫苗市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，以应对日益激烈的竞争。

COVID-19 疫苗市场中的 FPNV 定位矩阵供应商绩效评估

FPNV 定位矩阵是评估 COVID-19 疫苗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了 COVID-19 疫苗市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，对 COVID-19 疫苗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 冠状病毒的迅速传播导致许多人死亡
      • 政府对 COVID-19 疫苗的支持和津贴
      • 加强疫苗研发（R&D）倡议
    • 抑制因素
      • 全球发展中地区缺乏配套基础建设、技能和技术
    • 机会
      • 扩大合併活动以製造和分销 COVID-19 疫苗
      • 加大疫苗投资
    • 任务
      • 与 COVID-19 疫苗相关的副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 COVID-19 疫苗市场：依产品类型

  • 单价疫苗
  • 多效价疫苗

第 7 章 COVID-19 疫苗市场：按最终用户分类

  • 学术研究中心
  • 诊所
  • 医院
  • 疫苗接种中心

第 8 章按病患类型分類的 COVID-19 疫苗市场

  • 成人用
  • 小儿科
  • 老年人

第 9 章美洲 COVID-19 疫苗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太地区COVID-19疫苗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲的COVID-19疫苗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AIVITA Biomedical Inc.
  • AstraZeneca PLC
  • Baseimmune Ltd.
  • Bharat Biotech International Ltd.
  • Biological E. Ltd.
  • CanSino Biologics Inc.
  • Centivax Inc.
  • Codagenix Inc.
  • CureVac SE
  • Dr. Reddy's Laboratories Ltd.
  • Emergex Vaccines Holding Ltd.
  • Etherna Immunotherapies NV
  • Gennova Biopharmaceuticals Ltd.
  • GlaxoSmithKline PLC
  • HDT Bio, Inc.
  • Meissa Vaccines, Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novavax Inc.
  • Osivax SAS
  • Pfizer Inc.
  • Providence Therapeutics Inc.
  • SANOFI
  • Serum Institute of India Pvt. Ltd.
  • Sinovac Biotech Ltd.
  • Vaccitech PLC
  • Zydus Lifesciences Ltd.
Product Code: MRR-02026C4C976F

The COVID-19 Vaccines Market was valued at USD 215.43 billion in 2023, expected to reach USD 237.12 billion in 2024, and is projected to grow at a CAGR of 10.55%, to USD 434.83 billion by 2030.

The market research scope for COVID-19 vaccines encompasses the analysis of trends, market dynamics, and consumer behavior associated with vaccine development, distribution, and adoption. The necessity of these vaccines is imperative for global public health, aiming to mitigate the spread of the virus and reduce mortality rates, which directly influences economic recovery and societal well-being. The application of COVID-19 vaccines includes widespread immunization across demographic groups, addressing variants, and potential booster doses, with their end-use spanning the general public, healthcare sectors, and government and private entities. Market insights reveal key growth factors such as ongoing governmental support, a surge in public awareness, and advancements in mRNA technology that underpin vaccine innovation. However, emerging opportunities lie in expanding vaccine access to underserved regions through partnerships with international health organizations and improving supply chain logistics. These opportunities can be capitalized on by leveraging technological advancements and strategic alliances to bolster distribution networks. Limitations include vaccine hesitancy driven by misinformation, regulatory hurdles, and logistical challenges in storage and distribution, particularly in remote areas. Additionally, the virus's evolving nature and the emergence of new variants pose challenges that could alter vaccine efficacy and demand continuous research and adaptation. To navigate these challenges, businesses can innovate in areas such as vaccine storage technology, blockchain for supply chain management, and AI-driven research for adaptive vaccine formulations. The market is characterized by rapid advancements and intense competition, with players continuously seeking to enhance their offerings and expand their regional presence. Collaborations between pharmaceutical companies and tech firms could drive significant advancements in vaccine development and distribution efficiency, providing a comprehensive approach to combating COVID-19 and its evolving threats.

KEY MARKET STATISTICS
Base Year [2023] USD 215.43 billion
Estimated Year [2024] USD 237.12 billion
Forecast Year [2030] USD 434.83 billion
CAGR (%) 10.55%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving COVID-19 Vaccines Market

The COVID-19 Vaccines Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rapid spread of coronavirus resulting in a large number of deaths
    • Government support and grants for COVID-19 vaccines
    • Increasing research and development (R&D) initiatives for vaccines
  • Market Restraints
    • Limited supportive infrastructure, skills, and technology in developing areas around the world
  • Market Opportunities
    • Growing amalgamation activities to manufacture and distribute the COVID-19 vaccines
    • Rising investments for vaccines
  • Market Challenges
    • Side effects associated with the COVID-19 vaccines

Porter's Five Forces: A Strategic Tool for Navigating the COVID-19 Vaccines Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the COVID-19 Vaccines Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the COVID-19 Vaccines Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the COVID-19 Vaccines Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the COVID-19 Vaccines Market

A detailed market share analysis in the COVID-19 Vaccines Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the COVID-19 Vaccines Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the COVID-19 Vaccines Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the COVID-19 Vaccines Market

A strategic analysis of the COVID-19 Vaccines Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the COVID-19 Vaccines Market, highlighting leading vendors and their innovative profiles. These include AIVITA Biomedical Inc., AstraZeneca PLC, Baseimmune Ltd., Bharat Biotech International Ltd., Biological E. Ltd., CanSino Biologics Inc., Centivax Inc., Codagenix Inc., CureVac SE, Dr. Reddy's Laboratories Ltd., Emergex Vaccines Holding Ltd., Etherna Immunotherapies NV, Gennova Biopharmaceuticals Ltd., GlaxoSmithKline PLC, HDT Bio, Inc., Meissa Vaccines, Inc., Merck & Co., Inc., Moderna, Inc., Novavax Inc., Osivax SAS, Pfizer Inc., Providence Therapeutics Inc., SANOFI, Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., Vaccitech PLC, and Zydus Lifesciences Ltd..

Market Segmentation & Coverage

This research report categorizes the COVID-19 Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product Type, market is studied across Monovalent Vaccine and Multivalent Vaccine.
  • Based on End-User, market is studied across Academic & Research Centers, Clinics, Hospitals, and Vaccination Centers.
  • Based on Patient Type, market is studied across Adult, Pediatric, and Senior Citizens.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rapid spread of coronavirus resulting in a large number of deaths
      • 5.1.1.2. Government support and grants for COVID-19 vaccines
      • 5.1.1.3. Increasing research and development (R&D) initiatives for vaccines
    • 5.1.2. Restraints
      • 5.1.2.1. Limited supportive infrastructure, skills, and technology in developing areas around the world
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing amalgamation activities to manufacture and distribute the COVID-19 vaccines
      • 5.1.3.2. Rising investments for vaccines
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with the COVID-19 vaccines
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. COVID-19 Vaccines Market, by Product Type

  • 6.1. Introduction
  • 6.2. Monovalent Vaccine
  • 6.3. Multivalent Vaccine

7. COVID-19 Vaccines Market, by End-User

  • 7.1. Introduction
  • 7.2. Academic & Research Centers
  • 7.3. Clinics
  • 7.4. Hospitals
  • 7.5. Vaccination Centers

8. COVID-19 Vaccines Market, by Patient Type

  • 8.1. Introduction
  • 8.2. Adult
  • 8.3. Pediatric
  • 8.4. Senior Citizens

9. Americas COVID-19 Vaccines Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific COVID-19 Vaccines Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa COVID-19 Vaccines Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AIVITA Biomedical Inc.
  • 2. AstraZeneca PLC
  • 3. Baseimmune Ltd.
  • 4. Bharat Biotech International Ltd.
  • 5. Biological E. Ltd.
  • 6. CanSino Biologics Inc.
  • 7. Centivax Inc.
  • 8. Codagenix Inc.
  • 9. CureVac SE
  • 10. Dr. Reddy's Laboratories Ltd.
  • 11. Emergex Vaccines Holding Ltd.
  • 12. Etherna Immunotherapies NV
  • 13. Gennova Biopharmaceuticals Ltd.
  • 14. GlaxoSmithKline PLC
  • 15. HDT Bio, Inc.
  • 16. Meissa Vaccines, Inc.
  • 17. Merck & Co., Inc.
  • 18. Moderna, Inc.
  • 19. Novavax Inc.
  • 20. Osivax SAS
  • 21. Pfizer Inc.
  • 22. Providence Therapeutics Inc.
  • 23. SANOFI
  • 24. Serum Institute of India Pvt. Ltd.
  • 25. Sinovac Biotech Ltd.
  • 26. Vaccitech PLC
  • 27. Zydus Lifesciences Ltd.

LIST OF FIGURES

  • FIGURE 1. COVID-19 VACCINES MARKET RESEARCH PROCESS
  • FIGURE 2. COVID-19 VACCINES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL COVID-19 VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL COVID-19 VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL COVID-19 VACCINES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL COVID-19 VACCINES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES COVID-19 VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES COVID-19 VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. COVID-19 VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. COVID-19 VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. COVID-19 VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL COVID-19 VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL COVID-19 VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. COVID-19 VACCINES MARKET DYNAMICS
  • TABLE 7. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL COVID-19 VACCINES MARKET SIZE, BY MONOVALENT VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL COVID-19 VACCINES MARKET SIZE, BY MULTIVALENT VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL COVID-19 VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL COVID-19 VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL COVID-19 VACCINES MARKET SIZE, BY VACCINATION CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL COVID-19 VACCINES MARKET SIZE, BY SENIOR CITIZENS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES COVID-19 VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. COVID-19 VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. COVID-19 VACCINES MARKET, FPNV POSITIONING MATRIX, 2023